Email this article 
Post a Comment VEGF dynamical changes in laboratory rodents with transplanted experimental tumors of various histological types
- Authors: Trashkov A.P.1, Verlov N.A.1, Artemenko M.R.1, Pechatnikova V.A.1, Zelenenko M.A.2, Pakhomova M.A.3, Vasiliev A.G.3
-
Affiliations:
- Petersburg Nuclear Physics Institute named by B.P. Konstantinov of National Research Centre “Kurchatov Institute”
- Sechenov Institute of Ephysiology and Biochemistry, Russian Academy of Sciences
- St. Petersburg State Pediatric Medical University
- Issue: Vol 9, No 3 (2018)
- Pages: 49-56
- Section: Articles
- URL: https://journal-vniispk.ru/pediatr/article/view/9132
- DOI: https://doi.org/10.17816/PED9349-56
- ID: 9132
Cite item
Abstract
Vascular endothelial growth factor (VEGF) is one of the most important cytokines in charge of proliferation, migration and differentiation of endothelial cells in physiological and pathological processes. Because of this they are involved in pathogenesis of neoplasmatic process namely mechanisms of neoangiogenesis – development of blood-vessels’ network in the tumor as well as adjoining intact tissues. Almost all contemporary antiangiogenic medicines are targeted at either VEGF or its receptors. However, there are practically no conventional models of oncologic pathology nowadays described in detail and recommended for preclinical studies. The present study focuses at changes of VEGF concentrations at va rious stages of disease using experimental tumors of different histological types, intensity of neoplasmatic growth and localization. Development of experimental transplantable tumors of various histological types and locations has been demonstrated to be usually accompanied by increased VEGF blood serum concentration in experimental animals; the dynamic of this increase depending upon the intensity of the tumor growth. A statistically valid decrease of VEGF level in comparison with the previous control point of the study has been demonstrated in BALB/c male mice with subcutaneously transplanted colonic adenocarcinoma on the background of active development of the tumor at the 45th day of the study. Pliss’ Lymphoma, and Lymphocytal Leukemia Р-388 models have been demonstrated to be optimal for the assessment of medicines’ aimed at VEGF elimination pharmacological activity.
Full Text
##article.viewOnOriginalSite##About the authors
Alexander P. Trashkov
Petersburg Nuclear Physics Institute named by B.P. Konstantinov of National Research Centre “Kurchatov Institute”
Author for correspondence.
Email: alexandr.trashkov@gmail.com
MD, PhD, Head, Trials Center of Radiopharmaceutical
Russian Federation, GatchinaNikolay A. Verlov
Petersburg Nuclear Physics Institute named by B.P. Konstantinov of National Research Centre “Kurchatov Institute”
Email: virlov@gmail.com
PhD, Senior researcher, Trials Center of Radiopharmaceutical
Russian Federation, GatchinaMargarita R. Artemenko
Petersburg Nuclear Physics Institute named by B.P. Konstantinov of National Research Centre “Kurchatov Institute”
Email: shadow_ii@list.ru
Graduate, Trials Center of Radiopharmaceutical
Russian Federation, GatchinaValeria A. Pechatnikova
Petersburg Nuclear Physics Institute named by B.P. Konstantinov of National Research Centre “Kurchatov Institute”
Email: floluttrell@gmail.com
Researcher, Trials Center of Radiopharmaceutical
Russian Federation, GatchinaMaria A. Zelenenko
Sechenov Institute of Ephysiology and Biochemistry, Russian Academy of Sciences
Email: magu56110@gmail.com
MD, Researcher, Experimental Pharmacology Department
Russian Federation, Saint PetersburgMariya A. Pakhomova
St. Petersburg State Pediatric Medical University
Email: mariya.pahomova@mail.ru
Senior Researcher, Research Center
Russian Federation, Saint PetersburgAndrei G. Vasiliev
St. Petersburg State Pediatric Medical University
Email: avas7@mail.ru
MD, PhD, Dr. Med. Sci., Head, Pathophysiology Department
Russian Federation, Saint PetersburgReferences
- Герштейн Е.С., Щербаков А.М., Алиева С.К., и др. Фактор роста эндотелия сосудов в опухолях и сыворотке больных раком молочной железы: связь с клинико-морфологическими факторами // Вестник РОНЦ имени Н.Н. Блохина РАМН. - 2005. - Т. 16. - № 1-2. - С. 26-30. [Gershteyn ES, Shcherbakov AM, Alieva SK, et al. Vascular endothelial growth factor in tumors and serum of breast cancer patients: relation to clinicomorphological factors. Journal of N.N. Blokhin Russian Cancer Research Center RAMS. 2005;16(1-2): 26-30. (In Russ.)]
- Жуков Б.Н. Фотодинамическая терапия в комплексном лечении и реабилитации больных с острыми тромбозами глубоких вен нижних конечностей на фоне онкопатологии / Сборник тезисов Всероссийской научно-практической конференции «Посттромботическая болезнь»; Санкт-Петербург; 2009 г. - СПб.: СПбГУ, 2009. - С. 14-16. [Zhukov BN. Photodynamic therapy in the complex treatment and rehabilitation of patients with lower exteremities deep veins acute thrombosis on the background of oncopathology. In: Proceedings of the All-Russian scientific-practical conference «Post-thrombotic disease»; Saint Petersburg; 2009. Saint Petersburg: SPbGU; 2009. p. 14-16. (In Russ.)]
- Зубаиров Д.М., Адрушко И.А., Зубаирова Л.Д., Свинтенок Г.Ю. Пертурбация эндотелия - причина острой гиперкоагулемии // Казанский медицинский журнал. - 2002. - Т. 83. - № 5. - С. 327-333. [Zubairov DM, Andrushko IA, Zubairova LD, Svintenok GY, et al. Pertubation of endothelium the cause of acute hypercoagulemia. Kazan Med Zh. 2002;83(5):327-333. (In Russ.)]
- Мнихович М.В. Межклеточные и клеточно-матриксные взаимодействия в карциномах молочной железы: современное состояние проблемы // Российский медико-биологический вестник имени академика И.П. Павлова. - 2014. - № 2. - С. 152-161. [Mnihovich MV. Cell and cell-matrix interactions in breast carcinoma: the present state of problems. Rossiiskii mediko-biologicheskii vestnik imeni akademika I.P. Pavlova. 2014;(2):153-162. (In Russ.)]
- Степанова Е.В. Характеристика ангиогенной активности опухолей человека in vivo // Российский биотерапевтический журнал. - 2007. - Т. 6. - № 1. - С. 6-7. [Stepanova EV. Characteristic of angiogenic activity of human tumors in vivo. Rossiiskii bioterapevticheskii zhurnal. 2007;6(1):6-7. (In Russ.)]
- Степанова Е.В. Антиангиогенная терапия: новые возможности лечения злокачественных заболеваний // Практическая онкология. - 2002. - Т. 3. - № 4. - С. 246-252. [Stepanova EV. Angiogenic therapy: novel opportunities in the treatment of malignancies. Practical oncology. 2002;3(4):246-252. (In Russ.)]
- Трапезникова М.Ф., Глыбин П.А., Морозов А.П., и др. Ангиогенные факторы при почечно-клеточном раке // Онкоурология. - 2008. - № 4. - С. 82-87. [Trapeznikova MF, Glybin PA, Morozov AP, et al. Angiogenic factors in renal cell carcinoma. Onkourologiia. 2008;(4):82-87. (In Russ.)]
- Трашков А.П., Васильев А.Г., Цыган Н.В. Антитромботическая терапия в онкологии: современное состояние проблемы и нерешенные вопросы // Педиатр. - 2012. - Т. 3. - № 2. - С. 3-19. [Trashkov AP, Vasiliev AG, Tsygan NV. Antithrombotic therapy in oncology: contemporary concepts and pending problems. Pediatrician (St. Petersburg). 2012;3(2):3-19. (In Russ.)]
- Трашков А.П., Панченко А.В., Каюкова Е.С., и др. Лейкемия Р-388 у мышей линии CDF1 как тест-система опухоль-ассоциированного неоангиогенеза и гиперкоагуляции // Бюллетень экспериментальной биологии и медицины. - 2014. - Т. 158. - № 10. - С. 500-502. [Trashkov AP, Panchenko AV, Kayukova ES, et al. R-388 leukemia in СВА1 mice as tumor associated angiogenesis and hypercoagulation test system. Biull Eksp Biol Med. 2014;158(10):500-502. (In Russ.)]
- Шурыгин М.Г., Шурыгин И.А., Дремина Н.Н. Влияние фактора роста эндотелия сосудов на выраженность цитолиза при экспериментальном инфаркте миокарда // Acta biomedical scientifica. - 2008. - № 1. - С. 68-71. [Shurigin MG, Shurigina IA, Dremina NN. The influence of vessels endothelium growth factor on the cytolysis intensity at experimental cardiac infarction. Acta biomedica scientifica. 2008;(1):68-71. (In Russ.)]
- Anisimov VN, Popovich IG, Zabezhinski MA, et al. Sex differences in aging, life span and spontaneous tumorigenesis in 129/Sv mice neonatally exposed to metformin. Cell Cycle. 2015;14(1):46-55. doi: 10.4161/15384101.2014.973308.
- Cao Y, Ji WR, Qi P, et al. Placenta growth factor: identification and characterization of a novel isoform generated by RNA alternative splicing. Biochem Biophys Res Commun. 1997;235(3):493-498. doi: 10.1006/bbrc.1997.6813.
- Ebos JM, Lee CR, Cruz-Munoz W, et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009;15(3):232-239. doi: 10.1016/j.ccr.2009.01.021.
- Fagiani E, Christofori G. Angiopoietins in angiogenesis. Cancer Lett. 2013;328(1):18-26. doi: 10.1016/j.canlet.2012.08.018.
- Folberg R, Hendrix MJC, Maniotis AJ. Vasculogenic Mimicry and Tumor Angiogenesis. Am J Pathol. 2000;156(2):361-381. doi: 10.1016/s0002-9440(10)64739-6.
- Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285(21):1182-1186. doi: 10.1056/NEJM197111182852108.
- García-Román J, Zentella-Dehesa A. Vascular permeability changes involved in tumor metastasis. Cancer Lett. 2013;335(2):259-269. doi: 10.1016/j.canlet.2013.03.005.
- Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer. N Engl J Med. 2004;350(23):2335-2342. doi: 10.1056/NEJMoa032691.
- Liekens S, De Clercq E, Neyts J. Angiogenesis: regulators and clinical applications. Biochem Pharmacol. 2001;61(3):253-270. doi: 10.1016/s0006-2952(00)00529-3.
- Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009;15(3):220-231. doi: 10.1016/j.ccr.2009.01.027.
- Poveda A, Selle F, Hilpert F, et al. Weekly paclitaxel (PAC), pegylated liposomal doxorubicin (PLD) or topotecan (TOP)±bevacizumab (BEV) in platinum (PT)-resistant recurrent ovarian cancer (OC): analysis by chemotherapy (CT) cohort in the GCIG AURELIA randomised phase III trial. Ann Oncol. 2012;23(Suppl 9):LBA26.
- Takano S, Yoshii Y, Kondo S, et al. Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res. 1996;56(9):2185-2190.
Supplementary files
